At age 45, Dr. Lakiea Bailey said, for the longest time, that she was the oldest person with sickle cell anemia that she knew. The executive director of the nonprofit patient advocacy group the Sickle ...

A one-time gene-editing therapy, exagamglogene autotemcel (exa-cel), has demonstrated sustained and clinically meaningful ...

The FDA made a historic approval Dec. 8 when it cleared Casgevy, the nation’s first medicine based on CRISPR gene-editing technology, as a treatment for sickle cell disease. Its makers are now working ...

On Dec. 8, the FDA approved the nation’s first medicine based on CRISPR gene-editing technology to be used as a treatment for patients with sickle cell disease, a major scientific advancement that ...

LOS ANGELES (KABC) -- It's been more than a month since the FDA approved two milestone gene-editing treatments for sickle cell disease, but lining up patients for these therapies will be a challenge ...

In a 2025 qualitative analysis of payer insights conducted by McKesson and Lumanity, 20 payers representing nearly 280 million covered lives reported that although they broadly view CGTs as safe (90%) ...

In 2024, regulators approved Casgevy, the first CRISPR-based therapy to treat sickle cell disease and beta-thalassemia — a one-time treatment that edits a patient’s own stem cells to produce healthy ...

Vertex Pharmaceuticals Inc. (($VRTX)) announced an update on their ongoing clinical study. Vertex Pharmaceuticals Inc. is conducting a Phase 3 ...

Patients with sickle cell disease and beta-thalassemia treated with exagamglogene autotemcel reported substantial and ...

A new generation of CRISPR technology developed at UNSW Sydney offers a safer path to treating genetic diseases like Sickle Cell, while also proving beyond doubt that chemical tags on DNA - often ...

CRISPR Therapeutics is the first company to secure an FDA approval of a gene-editing drug. That drug's underlying science, however, could be used to create treatments for any number of genetically ...